Horner F, Lip PL, Mohammed BR, et al. - In this investigation involving 230 patients (249 eyes), researchers compared and reported the 2-year treatment outcomes from 3 different anti-VEGF treatment regimens in treating neovascular aged-related macular degeneration (nAMD): Ranibizumab pro re nata (Ranibizumab-PRN); Ranibizumab treat and extend (Ranibizumab-T&E); Aflibercept fixed first year dosing (7 injections) with treat and extend in subsequent year (Aflibercept-Fixed). The findings confirmed the superior efficacy of Aflibercept-Fixed and Ranibizumab-T&E regimens, and T&E was more efficient than PRN regimen when Ranibizumab therapy was considered. The cohort of long-term results from a real-world practice could also help clinicians consolidate decision-making when selecting the best-suited treatment regimen for individual patients during consultation.